Long non-coding RNAs in prostate cancer: Biological and clinical implications. (15th January 2019)

• Record Type: Journal Article
• Authors: Das, Rajdeep; Feng, Felix Y.; Selth, Luke A.
• Is Part Of: Molecular and cellular endocrinology. Volume 480(2019)
• Page Start: 142
• Page End: 152
• Publication Date: 2019-01-15
• Subjects: Prostate cancer -- Long non-coding RNAs -- lncRNAs -- Biomarker -- Therapy; Endocrinology -- Periodicals; Molecular biology -- Periodicals; Cytology -- Periodicals; Endocrinology -- Periodicals; Hormones -- Periodicals; Endocrinologie -- Périodiques; Cytology; Endocrinology; Molecular biology; Periodicals; 573.4
• DOI: 10.1016/j.mce.2018.10.023
• Languages: English
• ISSNs: 0303-7207

Abstract

Abstract: Prostate cancer (PCa) is a major health issue in the Western world. Current clinical imperatives for this disease include better stratification of indolent versus aggressive disease to enable improved patient management, as well as the identification of more effective therapies for the prevention and treatment of metastatic and therapy-resistant PCa. The advent of next-generation transcriptomics led to the identification of an important class of molecules, long non-coding RNAs (lncRNAs). LncRNAs have critical functions in normal physiology, but their dysregulation has also been implicated in the development and progression of a variety of cancers, including PCa. Importantly, a subset of lncRNAs are highly prostate-specific, suggesting potential for utility as both biomarkers and therapeutic targets. In this review, we summarise the biology of lncRNAs and their mechanisms of action in the development and progression of prostate cancer. Additionally, we cast a critical eye over the potential for this class of molecules to impact on clinical practice. Highlights: Long non-coding RNAs (lncRNAs) play critical roles in the pathophysiology of prostate cancer. There is extensive interplay between the androgen receptor signalling (AR) axis and lncRNAs. Urine-based lncRNA biomarker assays have clinical potential for the diagnosis and/or management of prostate cancer. LncRNA-targeted therapies have potential in prostate cancer, but clinical translatability is a major challenge.